Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-012170
Filing Date
2022-05-05
Accepted
2022-05-05 08:16:23
Documents
72
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 572563
2 ex31-1.htm EX-31.1 18743
3 ex31-2.htm EX-31.2 18671
4 ex32-1.htm EX-32.1 6916
5 ex32-2.htm EX-32.2 6941
  Complete submission text file 0001493152-22-012170.txt   3496718

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE xtnt-20220331.xsd EX-101.SCH 31189
7 XBRL CALCULATION FILE xtnt-20220331_cal.xml EX-101.CAL 60165
8 XBRL DEFINITION FILE xtnt-20220331_def.xml EX-101.DEF 87446
9 XBRL LABEL FILE xtnt-20220331_lab.xml EX-101.LAB 266969
10 XBRL PRESENTATION FILE xtnt-20220331_pre.xml EX-101.PRE 205485
66 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 424701
Mailing Address 664 CRUISER LANE BELGRADE MT 59714
Business Address 664 CRUISER LANE BELGRADE MT 59714 406-388-0480
Xtant Medical Holdings, Inc. (Filer) CIK: 0001453593 (see all company filings)

EIN.: 205313323 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34951 | Film No.: 22894197
SIC: 2836 Biological Products, (No Diagnostic Substances)